Lytix Biopharma AS
OSE:LYTIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lytix Biopharma AS
Revenue
Lytix Biopharma AS
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Revenue
kr11.1m
|
CAGR 3-Years
723%
|
CAGR 5-Years
105%
|
CAGR 10-Years
N/A
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Revenue
kr256.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
30%
|
CAGR 10-Years
17%
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Revenue
kr112.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Revenue
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Revenue
kr439k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
Lytix Biopharma AS
Glance View
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.
See Also
What is Lytix Biopharma AS's Revenue?
Revenue
11.1m
NOK
Based on the financial report for Dec 31, 2024, Lytix Biopharma AS's Revenue amounts to 11.1m NOK.
What is Lytix Biopharma AS's Revenue growth rate?
Revenue CAGR 5Y
105%
Over the last year, the Revenue growth was 179%. The average annual Revenue growth rates for Lytix Biopharma AS have been 723% over the past three years , 105% over the past five years .
